Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms MOBILITY; RA-MOBILITY; SARIL-RA-MOBILITY
- Sponsors Sanofi
- 22 Nov 2022 Results of pooled analysis from (NCT01061736, NCT02332590, NCT01709578, NCT01146652) assessing disproportionate articular pain prevalence and effects of sarilumab published in the Rheumatology
- 25 Aug 2022 Results of pooled post hoc analyses assessing clinical outcomes from three phase III trials: TARGET, MOBILITY, and MONARCH published in the Arthritis Research and Therapy
- 01 May 2022 Results of a pharmacogenomic study (n=1075) assessing genetic variation in UGT1A1 using data from three clinical studies: MOBILITY, TARGET, and ASCERTAIN published in the Pharmacogenomics Journal